Leuprolide and Dofetilide: Interaction Details
- Dofetilide
- Tikosyn
- Leuprolide
- LupronFensolviCamcevi +8 more
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Leuprolide and Dofetilide interaction:
Leuprolide
- Lupron
- Fensolvi
- Camcevi
- Lutrate
- Vabrinty
- Eligard
- Lupron Depot
- Lupron Depot-PED
- Camcevi Etm
- Leuprolide Acetate Depot
- Lutrate Depot
What Happens When You Take Leuprolide With Dofetilide
What can happen when they are taken together (rated Major)
Increased risk of
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Androgen deprivation produced by leuprolide has the potential to lengthen the QT/. In patients who are also receiving medications known to prolong the , weigh whether the benefits of androgen deprivation therapy exceed the possible risks.14
Where feasible, do not use leuprolide together with agents that prolong the QT interval. When cannot be avoided, steer clear of drugs that lead to electrolyte disturbances (ie, or ),2 and consider checking the and electrolytes at regular intervals.14
The Leuprolide and Dofetilide Interaction, Explained
Both of these medicines can affect your heart's electrical rhythm. Dofetilide (Tikosyn) is used to keep the heart in a normal rhythm for atrial fibrillation, and it can lengthen the heart's recovery time between beats (called the ). Leuprolide (Lupron, Eligard and others) lowers male hormones and may also lengthen the QT interval a bit. Taken together, the effect may add up and raise the chance of a dangerous heart rhythm. This concern is based mostly on theory, not on proven cases.
Please keep taking both as prescribed. Talk with your pharmacist or doctor, who can weigh the benefits, check your heart tracing () and blood salts like potassium and magnesium, and manage this safely.
QT/ (). Dofetilide is a potassium channel (IKr) blocker with a and known risk. Leuprolide-induced androgen deprivation may prolong QT/. Neither is relevant as a issue; the concern is additive repolarization effect, not altered PK. Evidence is theoretical, onset unspecified, severity rated major.
- Weigh benefit of ADT against arrhythmic risk; avoid with QT-prolonging agents when possible.
- If required, avoid agents causing or .
- Consider periodic and electrolyte (K, Mg) monitoring, in addition to dofetilide's standard QTc and function monitoring.
See the 4 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Leuprolide and Dofetilide Interact
The likely mechanism
How to Manage the Leuprolide and Dofetilide Interaction
Your care team can manage this, and the usual approach is careful risk review and monitoring.
- Keep taking both medicines as prescribed unless your prescriber tells you otherwise.
- Your team will weigh whether the benefit of leuprolide outweighs the heart rhythm risk, and may avoid other QT-prolonging medicines when possible.
- They may avoid medicines that lower potassium or magnesium, and may check your and blood electrolytes periodically.
- Tell your pharmacist or doctor about all medicines you take, and report fainting, dizziness, or a racing or irregular heartbeat right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Leuprolide or Dofetilide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes
A study of male patients treated with androgen deprivation therapy (ADT) analyzed individual case safety reports in VigiBase, the international pharmacovigilance database, and found 184 cases of acquired long-QT syndrome (aLQTS) and/or (TdP; 11% of cases fatal) and 99 cases of sudden death linked to ADT. Most ADT-associated cases of aLQTS/TdP (62%) and sudden death (88%) occurred without exposure to other drugs known to raise TdP risk.
Still, exposure to 1 drug with conditional, possible, or known TdP risk was reported in some aLQTS/TdP (23%) and sudden death (18%) events, and exposure to 2 or more such drugs was reported in 43% of aLQTS/TdP and 22% of sudden death events. The drugs classed as ADTs were abiraterone, gonadotropin-releasing hormone and , nonsteroidal androgen receptor indicated for prostate cancer, and 5-alpha-reductase inhibitors indicated for androgenic alopecia and prostatism.
Of the 10 ADTs assessed, 7 showed a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death: leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. The median patient age was about 76 years.
The median time to onset was 170 days (range, 7 to 4884 days) for aLQTS/TdP events and 92 days (range, 0.25 to 4984 days) for sudden death events. Patients received ADT mainly for prostate cancer, and some received it for prostatism and androgenic alopecia. Most patients were on ADT monotherapy (83%), while 17% were on ADT combination therapy.3
Leuprolide and Dofetilide: Common Questions
How serious is the Leuprolide and Dofetilide interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Leuprolide and Dofetilide interaction managed?
Your care team can manage this, and the usual approach is careful risk review and monitoring. Keep taking both medicines as prescribed unless your prescriber tells you otherwise. Your team will weigh whether the benefit of leuprolide outweighs the heart rhythm risk, and may avoid other QT-prolonging medicines when possible. They may avoid medicines that lower potassium or magnesium, and may check… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Leuprolide and Dofetilide Interaction
Ask in your own words about taking Leuprolide and Dofetilide together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (4)
- Product Information: CAMCEVI ETM subcutaneous emulsion, leuprolide subcutaneous emulsion. Foresee Pharmaceuticals (per FDA), Newark, DE, 2025. DailyMed
- Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361. DailyMed
- Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. DailyMed
- Product Information: ELIGARD(R) subcutaneous injection suspension, leuprolide acetate subcutaneous injection suspension. Tolmar Pharmaceuticals, Inc. (per FDA), Fort Collins, CO, 2016.
Other Serious Interactions of Leuprolide and Dofetilide
Also serious with Dofetilide
- CephalexinContraindicated
- CimetidineContraindicated
- DolutegravirContraindicated
- DronedaroneContraindicated
Also serious with Leuprolide
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Dofetilide
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- American HelleboreMajor
- ArsenicMajor
- CesiumMajor
- EphedraMajor
- Sida CordifoliaMajor
- + 143 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.